Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...

A single-dose vial of Mounjaro costs Rs. 3,500 for 2.5 mg or Rs. 4,375 for 5 mg. On a typical weekly dose, that adds up to ...

Talent Acquisition and Retention Pose Major Challenges for Life Sciences GCCs - Talent retention and acquisition are top ...

Kamath flagged that most of the world — including India — still doesn’t fully understand the long-term impact of these drugs.

JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...

A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...